Inovio Pharmaceuticals Inc., of Plymouth Meeting, Pa., received a five-year award of up to $56 million from the Coalition for Epidemic Preparedness Innovations to support preclinical and clinical development through phase II of INO-4500, a vaccine against Lassa fever, and INO-4700, a vaccine for Middle East respiratory syndrome.